The global market for coagulation factor concentrates is currently worth $7.8 billion. The Fact.MR industry assessment predicts that between 2022 and 2027, sales of coagulation factor concentrates will increase at a decent CAGR of 7.8%.
The coagulation factor concentrates market is expected to grow over the next five years due to rising healthcare R&D costs and the rising prevalence of blood disorders. A high prevalence of hemophilia, increased use of preventative treatment, and government initiatives to enhance awareness of blood illnesses are further factors that could propel sales of coagulation factor concentrate till 2027.
However, it is anticipated that a lack of knowledge about blood disorders in emerging and developing countries may partially restrain market expansion.
For Critical Insights on Coagulation Factor Concentrates Market, Request a Sample Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7677
Key Drivers of Coagulation Factor Concentrates Market Growth
The market for coagulation factor concentrates is poised for growth over the next five years, driven by factors such as the increasing adoption of prophylactic treatments, a rising incidence of hemophilia in newborns, growing demand for hemophilia therapies, and significant investments in healthcare research and development.
However, challenges such as the high costs of treating blood disorders and limited awareness of these conditions in developing regions could restrain market potential.
Geographic Outlook for the Coagulation Factor Concentrates Market
"North America and Europe to Lead Global Coagulation Factor Concentrates Growth"
-
North America:
The North American market is anticipated to maintain a dominant share through 2027, supported by rapid adoption of innovative treatments, advanced healthcare infrastructure, and robust healthcare R&D investments. In Canada, the market is projected to grow at a CAGR of 6.4% over the next five years. -
Europe:
Europe is expected to see strong growth, fueled by rising healthcare infrastructure investments and government initiatives to increase awareness of blood disorders. Key markets include France, Germany, Italy, and the United Kingdom. The German market is forecasted to grow at a CAGR of 4.5% through 2027. -
Asia Pacific:
The Asia Pacific region is set to expand due to a large patient population with blood-related disorders and increased healthcare infrastructure development. India, with its high prevalence of hemophilia, is expected to emerge as a significant market in this region.
Country-wise Insights
The growing frequency of blood disorders and increased investments in the R&D sector are expected to propel the coagulation factor concentrates market in the United States. The market for treating bleeding disorders is anticipated to benefit from high healthcare costs and the expanding use of innovative treatments and therapies, which will in turn fuel demand for coagulation factor concentrate.
The market potential for coagulation factor concentrates in the United States is also anticipated to be positively impacted by increases in government spending to support research and development activities as well as campaigns to raise awareness of blood-related illnesses.
Coagulation factor concentrate sales in the US are expected to generate US$2 billion in revenue in 2022.
Category-wise Insights
Coagulation factor IX, coagulation factor XIII, and other variants comprise the market for coagulation factor concentrates worldwide.
Because coagulation factor XIII has a better safety record and is widely used to treat hemophilia A and hemophilia B disorders, its demand is expected to be higher than that of coagulation factor IX. Similar to plasma-derived coagulation factor concentrates, coagulation factor XIII is developed by inactivating viruses, which improves its quality and safety profile.
This study of the coagulation factor concentrates market also offers comprehensive predictions about the future of demand for coagulation factor IX and other coagulation factor varieties.
Strategies by Coagulation Factor Concentrate Providers
Key players in the coagulation factor concentrates market are focusing on enhancing their revenue streams through regulatory approvals for innovative products.
-
Novo Nordisk's FDA Approval:
- In July 2022, Novo Nordisk received FDA approval for REBINYN® (Coagulation Factor IX, GlycoPEGylated).
- This product is a recombinant DNA-derived coagulation factor IX concentrate designed for regular prophylaxis in both adults and children.
-
Recent Developments by Major Companies:
- Prominent market players, including Baxter International Inc., Octapharma, LFB, Biotest, Green Cross Corporation, Shanghai RAAS Blood Products, and Sanquin, have introduced significant advancements and initiatives.
- These developments aim to strengthen their product portfolios and address the growing demand for coagulation factor concentrates globally.
These strategic moves underline the competitive nature of the market and the emphasis on innovation to meet evolving healthcare needs.
Key Segments in Coagulation Factor Concentrates Industry Research
-
By Type :
- Coagulation Factor IX
- Coagulation Factor XIII
- Other Types
-
By End User :
- Hospitals & Clinics
- Research Laboratories
- Academic Institutions
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Comments
0 comment